 |
|
Adenosine receptors as emerging therapeutic targets for diabetic kidney disease
Eun Seon Pak, Jin Joo Cha, Dae Ryong Cha, Keizo Kanasaki, Hunjoo Ha
Kidney Res Clin Pract. 2022;41(Suppl 2):S74-S88. Published online 2022 Aug 22 DOI: https://doi.org/10.23876/j.krcp.22.011
|
|
Citations to this article as recorded by
 Defective insulin-stimulated equilibrative nucleoside transporter-2 activity and altered subcellular transporter distribution drive the loss of adenosine homeostasis in diabetic kidney disease progression
Raibel Suarez, Carolina Villarreal, Yessica Nahuelpán, Claudia Jara, Carlos Oyarzún, Sebastián Alarcón, Montserrat M. Díaz-Encarnación, Elena Guillén-Gómez, Claudia Quezada, Rody San Martín
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2024; 1870(1): 166890. CrossRef Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis
Eun Sil Koh, Gheun-Ho Kim, Sungjin Chung
Endocrinology and Metabolism.2023; 38(4): 359. CrossRef Diabetic kidney disease, revisited: where do we stand?
Dae Ryong Cha
Kidney Research and Clinical Practice.2022; 41(Suppl 2): S31. CrossRef
|